The consensus EPS Estimate is $1.68 (vs $0.03 in Q4 2023) and the consensus Revenue Estimate is $15.51B (+6.2% Y/Y). Over the last 2 years, MRK has beaten EPS estimates 88% of the time and has ...
Q4 2024 Results Conference Call March 6, 2025 8:00 AM ETCompany ParticipantsFlorian Schraeder - Head of Investor ...
Hosted on MSN1mon
Merck shares tumble on Q4 earnings miss, weak 2025 guidanceMerck (NSE:PROR) posted adjusted earnings per share (EPS) of $1.72 for Q4, missing the analyst consensus of $1.81 by $0.09. However, revenue for the quarter came in at $15.6 billion, beating the ...
Merck (MRK) came out with quarterly earnings of $1.72 per share, beating the Zacks Consensus Estimate of $1.69 per share. This compares to earnings of $0.03 per share a year ago. These figures are ...
Electronics EBITDA Pre Margin (Q4 2024): 25.6%. Guidance for 2025 Sales: EUR21.5 billion to EUR22.9 billion. Guidance for 2025 EBITDA Pre: EUR6.1 billion to EUR6.6 billion. Merck KGaA (MKGAF ...
(RTTNews) - Biopharmaceutical company Merck & Co., Inc. (MRK) reported Tuesday a net profit for the fourth quarter compared to a loss last year, reflecting improved gross margins, sharply lower R ...
Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK may work for income investors.
RAHWAY, N.J. (AP) — RAHWAY, N.J. (AP) — Merck & Co. (MRK) on Tuesday reported fourth-quarter net income of $3.74 billion. On a per-share basis, the Rahway, New Jersey-based company said it had ...
Merck unveils a $1 billion vaccine manufacturing facility in Durham, North Carolina, expanding its U.S. production and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback